Amarpreet Sawhney is the Chairman and CEO OF Instylla Inc which is developing new liquid embolics for tumor embolization and hemostasis. He is also CEO of Rejoni Inc., which is developing products to prevent adhesions following gynecological interventions. He is also the Founding partner and CEO of Pramand LLC, which is developing products for surgical sealing and hemostasis. Previously he was President and CEO of Ocular Therapeutix, Inc. (OCUL: NASDAQ) a company focused on unmet needs in ophthalmic drug delivery. He was also the Chairman of Augmenix, Inc. (acquired by Boston Scientific), Founder and CEO of Confluent Surgical (acquired by Covidien), the Chairman of MarketRx (acquired by Cognizant), a provider of pharmaceutical marketing and sales analytics and intelligence, technology founder of Focal, Inc. (acquired by Genzyme) and Access Closure Inc. (acquired by Cardinal Health). He holds over 150 patents, which form the basis for several first-of-a-kind medical devices that have helped over 10 million patients worldwide. He has founded 10 companies, which account for over 5,000 jobs created and over $3 billion in revenue to date. Dr. Sawhney helps foster entrepreneurship by mentoring young innovators and creating companies through Incept, a medical device incubator. Dr. Sawhney holds a Ph.D. and M.S. in Chemical Engineering from the University of Texas at Austin and a B.Tech. in Chemical Engineering from IIT Delhi.